NasdaqGS:TEMLife Sciences
Assessing Tempus AI (TEM) Valuation After New Immune Profile Score Breakthrough
Tempus AI (TEM) has drawn fresh attention after releasing clinical validation data on its Immune Profile Score test, which the company reports more accurately predicts which cancer patients benefit from immune checkpoint inhibitors than conventional biomarkers.
See our latest analysis for Tempus AI.
Those IPS results arrive after a busy month for Tempus AI, with the launch of Paige Predict in digital pathology and fresh attention from high profile investors such as ARK and Nancy Pelosi. Even...